OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Gastroenterology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Revisiting the relationship between thyroid function and metabolic dysfunction-associated steatotic liver disease in the era of resmetirom	115
Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus	75
Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism	73
Induction of ferroptosis by photodynamic therapy and enhancement of antitumor effect with ferroptosis inducers	68
Bifidobacterium bifidum CIP-01 attenuates metabolic dysfunction-associated steatotic liver disease induced by high-alcohol-producing Klebsiella pneumoniae	62
Corynoline protects chronic pancreatitis via binding to PSMA2 and alleviating pancreatic fibrosis	61
Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn’s disease	56
Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma	54
Managing radiation safety and protection in gastroenterology in Japan: insights from the REX-GI study	49
Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy	49
Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy	46
Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospectiv	44
Single-cell transcriptomics unveils the immunologic landscape of anti-PD-1-associated indirect drug-induced liver injury	39
High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy	39
Clinicopathological features and prognosis of primary small bowel adenocarcinoma: a large multicenter analysis of the JSCCR database in Japan	37
Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data	36
Reply to: Minocycline versus tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial	36
Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis	36
Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy	35
Clinicopathological features of localized-type IgG4-related cholecystitis: a nationwide multicenter study in Japan	33
Clinical practice guidelines for duodenal cancer 2021	32
Associations between excessive supragastric belching and esophageal reflux factors in patients with PPI-refractory GERD in Japan	32
Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials	32
Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database	31
Predictive factors for the progression of primary localized stage small-bowel follicular lymphoma	31

Novel subharmonic-aided pressure estimation for identifying high-risk esophagogastric varices	30
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis	30
Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey	29
Acknowledgements	29